JPRN-jRCTs051230014招募中2 期
A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal cancer. (AMBITION) - AMBITIO
emura Mamoru0 个研究点目标入组 45 人开始时间: 2023年4月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The patient has been fully informed of the contents of the study and has given written consent.
- •2. The patient has adenocarcinoma of the rectum confirmed by histological examination.
- •3. No distant metastases are detected on imaging studies, and radical resection is clinically feasible.
- •4. Age of 20 years or older on the date of consent.
- •5. ECOG Performance Status (PS) is 0 - 1 (PS 0 for age 71 years or older on the date of consent).
- •6. Previously untreated rectal cancer with the lower margin of the tumor within 12 cm of the anal verge (AV).
- •7. Patients with cT2N0M0 in the diagnosis before starting treatment (a lymph node with a short diameter of 7 mm or more is considered positive).
- •The conditions for lymph node metastasis shall be as follows.
- •Contrast-enhanced CT or MRI (plain or contrast-enhanced) with a slice width of 5 mm or less.
- •(i) Short diameter of 10 mm or more
- •(ii) Short diameter of 7 mm or more and one or more of the following a) to c) are met
- •(a) Edge irregularity
- •(b) Low signal area with internal heterogeneity on MRI
- •(c) Circular (long/short diameter ratio < 1.5)
- •If contrast-enhanced CT is not possible due to contrast medium allergy, renal dysfunction, or bronchial asthma, simple CT is acceptable.
- •8. The following criteria for major organ function within 28 days prior to registration are met.
- •If more than one test result exists within this period, the most recent one should be used. No blood transfusions or hematopoietic factor products should be administered within 28 days prior to the test date.
- •a. Neutrophil count: greater than or equal to 1,500/mm3
- •b. Platelet count: >= 10.0 x 104 /mm3
- •c. Hemoglobin concentration: >=9.0 g/dL
- •d. Total bilirubin: 1.5 times or less than the upper limit of the institutional standard
- •e. AST, ALT, ALP: 2.5 times or less than the upper limit of the institutional standard
- •f. Serum creatinine: 1.5 times or less than the upper limit of the institutional standard or creatinine clearance: 45 mL/min or more
排除标准
- •1. underwent treatment by any of the following within a certain period of time prior to initiation of protocol therapy
- •a. extensive surgery (excluding CV port placement) within 4 weeks
- •b. Any anticancer therapy within 4 weeks
- •c. Radiation within 4 weeks
- •2. concomitant or pre-existing severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.)
- •3. patients who have had a colonic stent implanted
- •4. patients with serious comorbidities (heart failure, renal failure, liver failure, bleeding peptic ulcer, intestinal paralysis, bowel obstruction, poorly controlled diabetes, etc.)
- •5. patients with active multiple overlapping cancers (synchronous multiple overlapping cancers or iatrogenic multiple overlapping cancers with a disease-free period of 5 years or less). However, carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma that is considered curable by local treatment is not considered active multiple overlapping carcinoma.
- •6. pregnant or lactating women, positive pregnancy test or unwillingness to use contraception
- •7. HBs antigen positive .
- •8. has known human immunodeficiency virus (HIV) infection.
- •9. otherwise judged by the principal investigator or subinvestigator to be unsuitable for this study.
研究者
相似试验
进行中（未招募）
1 期
A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaCytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemiaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104CTIS2023-507899-47-00Goethe University Frankfurt40
进行中（未招募）
1 期
Research study to determine whether a drug called obinutuzumab given to persons with relapsed and refractory Waldenström Macroglobulinemia in induction therapy followed by two years of maintenance is safe and efficacious.EUCTR2016-005053-20-PLPolish Myeloma Consortium30
进行中（未招募）
1 期
Clinical study aimed to assess in patients with triple-negative operable breast cancer the activity of the drug zoledronate administered before surgery, according to the the tumor aggressiveness (determined by the level of expression of the p53 protein)ewly diagnosed, untreated, operable triple negative breast cancerMedDRA version: 18.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-004194-16-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI21
招募中
不适用
A multicenter, single arm phase 2 study to examine efficacy and cerebrospinal fluid transitivity of Osimertinib in leptomeningeal carcinomatosis (LMC) patients with non-small cell lung cancer harboring EGFR mutatioJPRN-UMIN000023710HANSHI15
招募中
1 期
Treatment for breast cancer patients with meninges invaded by tumor cellsPatients having a HER2-amplified metastatic breast cancer with evolutive leptomeningeal metastases (LM) requiring intrathecal therapyCTIS2022-502351-60-00nicancer30